Binimetinib
Brand: Mektovi (global)
Anticancer
MEK inhibitor
Pharmacokinetics
| Half-life | 9 hours |
| Tmax | 1.5 h |
| Clearance Route | hepatic |
| Active Metabolites | yes |
| Notes | Often combined with Encorafenib. Monitor LFT and ocular toxicity. |
⚠️ Safety & Warnings
Severity: Severe
Adverse Effects:
Retinal pigment epithelial detachment, CPK elevations, hepatotoxicity, diarrhea
Contraindications:
Severe ocular disease
Precautions:
Baseline and periodic ophthalmologic exams recommended.